The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
   Google Scholar
• Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primers. 2018;4(1):18008. doi:10.1038/nrdp.2018.8
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–251. doi:10.1001/archgenpsychiatry.2011.12
   PubMed Web of Science ®Google Scholar
• Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiat. 2016;3(2):171–178. doi:10.1016/S2215-0366(15)00505-2
   PubMed Web of Science ®Google Scholar
• Rosa AR, Reinares M, Michalak EE, et al. Functional impairment and disability across mood states in bipolar disorder. Value Health. 2010;13(8):984–988. doi:10.1111/j.1524-4733.2010.00768.x
   PubMed Web of Science ®Google Scholar
• Jin H, McCrone P. Cost-of-illness studies for bipolar disorder: systematic review of international studies. Pharmacoeconomics. 2015;33(4):341–353. doi:10.1007/s40273-014-0250-y
   PubMed Web of Science ®Google Scholar
• Moreno C, Hasin DS, Arango C, et al. Depression in bipolar disorder versus major depressive disorder: results from the national epidemiologic survey on alcohol and related conditions. Bipolar Disord. 2012;14(3):271–282. doi:10.1111/j.1399-5618.2012.01009.x
   PubMed Web of Science ®Google Scholar
• Rubio JM, Olfson M, Perez-Fuentes G, Garcia-Toro M, Wang S, Blanco C. Effect of first episode axis I disorders on quality of life. J Nerv Ment Dis. 2014;202(4):271–274. doi:10.1097/NMD.0000000000000117
   Web of Science ®Google Scholar
• Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics. 2001;19(5 Pt 1):483–495. doi:10.2165/00019053-200119050-00004
   PubMed Web of Science ®Google Scholar
• Kleine-Budde K, Touil E, Moock J, Bramesfeld A, Kawohl W, Rossler W. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord. 2014;16(4):337–353. doi:10.1111/bdi.12165
   PubMed Web of Science ®Google Scholar
• Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness–1991. Soc Psychiatry Psychiatr Epidemiol. 1995;30(5):213–219. doi:10.1007/BF00789056
   PubMed Web of Science ®Google Scholar
• Centorrino F, Mark TL, Talamo A, Oh K, Chang J. Health and economic burden of metabolic comorbidity among individuals with bipolar disorder. J Clin Psychopharmacol. 2009;29(6):595–600. doi:10.1097/JCP.0b013e3181bef8a6
   PubMed Web of Science ®Google Scholar
• Goldstein BI, Liu SM, Zivkovic N, Schaffer A, Chien LC, Blanco C. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord. 2011;13(4):387–395. doi:10.1111/j.1399-5618.2011.00932.x
   PubMed Web of Science ®Google Scholar
• Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JR. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord. 2010;12(4):404–413. doi:10.1111/j.1399-5618.2010.00823.x
   Web of Science ®Google Scholar
• Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013;170(3):265–274. doi:10.1176/appi.ajp.2012.12050620
   PubMed Web of Science ®Google Scholar
• Fajutrao L, Locklear J, Priaulx J, Heyes A. A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemiol Ment Health. 2009;5(1):3. doi:10.1186/1745-0179-5-3
   Google Scholar
• Blanco C, Compton WM, Saha TD, et al. Epidemiology of DSM-5 bipolar I disorder: results from the national epidemiologic survey on alcohol and related conditions – III. J Psychiatr Res. 2017;84:310–317. doi:10.1016/j.jpsychires.2016.10.003
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62(12):1322–1330. doi:10.1001/archpsyc.62.12.1322
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry. 2007;64(5):543–552. doi:10.1001/archpsyc.64.5.543
   PubMed Web of Science ®Google Scholar
• Westman J, Hallgren J, Wahlbeck K, Erlinge D, Alfredsson L, Osby U. Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden. BMJ Open. 2013;3(4):e002373. doi:10.1136/bmjopen-2012-002373
   PubMed Web of Science ®Google Scholar
• Rhee TG, Olfson M, Nierenberg AA, Wilkinson ST. 20-Year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry. 2020;appiajp202019091000.
   Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.
   PubMed Web of Science ®Google Scholar
• Ostacher MJ, Tandon R, Suppes T. Florida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: a novel, practical, patient-centered guide for clinicians. J Clin Psychiatry. 2016;77(7):920–926. doi:10.4088/JCP.15cs09841
   Web of Science ®Google Scholar
• NICE. Bipolar Disorder: Assessment and Management. NICE Clinical Guideline 185. London: National Institute for Health and Care Excellence; 2014.
   Google Scholar
• Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087–1206. doi:10.1177/0004867415617657
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry. 2018;19(1):2–58. doi:10.1080/15622975.2017.1384850
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British association for psychopharmacology. J Psychopharmacol. 2016;30(6):495–553. doi:10.1177/0269881116636545
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Grunze H, Vieta E, et al. The international college of neuro-psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol. 2017;20(2):180–195. doi:10.1093/ijnp/pyw109
   PubMed Web of Science ®Google Scholar
• Frank RG, Beronio K, Glied SA. Behavioral health parity and the affordable care act. J Soc Work Disabil Rehabil. 2014;13(1–2):31–43. doi:10.1080/1536710X.2013.870512
   PubMedGoogle Scholar
• United States Bureau of Labor Statistics. Consumer price index; 2018. Available from: http://www.bls.gov/cpi/. Accessed January 18, 2019.
   Google Scholar
• Cloutier M, Greene M, Guerin A, Touya M, Wu E. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;226:45–51. doi:10.1016/j.jad.2017.09.011
   PubMed Web of Science ®Google Scholar
• Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord. 2011;129(1–3):79–83. doi:10.1016/j.jad.2010.08.030
   PubMed Web of Science ®Google Scholar
• Bagalman E, Muser E, Choi JC, et al. Health care resource utilization and costs in a commercially insured population of patients with bipolar disorder type I and frequent psychiatric interventions. Clin Ther. 2011;33(10):1381–1390.e1384. doi:10.1016/j.clinthera.2011.09.005
   Web of Science ®Google Scholar
• Durden E, Bagalman E, Muser E, et al. Characteristics, healthcare utilization and costs of bipolar disorder type I patients with and without frequent psychiatric intervention in a medicaid population. J Med Econ. 2010;13(4):698–704. doi:10.3111/13696998.2010.531828
   Google Scholar
• Jing Y, Kim E, You M, Pikalov A, Tran QV. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. J Med Econ. 2009;12(2):104–113. doi:10.3111/13696990903044092
   PubMedGoogle Scholar
• Tohen M, Ng-Mak D, Rajagopalan K, Halpern R, Chuang CC, Loebel A. Patient characteristics associated with use of lurasidone versus other atypical antipsychotics in patients with bipolar disorder: analysis from a claims database in the United States. Prim Care Companion CNS Disord. 2017;19(3). doi:10.4088/PCC.16m02066
   Google Scholar
• Williams MD, Shah ND, Wagie AE, Wood DL, Frye MA. Direct costs of bipolar disorder versus other chronic conditions: an employer-based health plan analysis. Psychiatr Serv. 2011;62(9):1073–1078. doi:10.1176/ps.62.9.pss6209_1073
   PubMed Web of Science ®Google Scholar
• Lum TY, Parashuram S, Shippee TP, et al. Diagnosed prevalence and health care expenditures of mental health disorders among dual eligible older people. Gerontologist. 2013;53(2):334–344. doi:10.1093/geront/gns163
   PubMed Web of Science ®Google Scholar
• Haskins JT, Macfadden W, Turner N, et al. Clinical characteristics and resource utilization of patients with bipolar disorder who have frequent psychiatric interventions. J Med Econ. 2010;13(3):552–558. doi:10.3111/13696998.2010.511064
   PubMedGoogle Scholar
• Lang K, Korn J, Muser E, Choi JC, Abouzaid S, Menzin J. Predictors of medication nonadherence and hospitalization in medicaid patients with bipolar I disorder given long-acting or oral antipsychotics. J Med Econ. 2011;14(2):217–226. doi:10.3111/13696998.2011.562265
   PubMedGoogle Scholar
• Stensland M, Watson PR, Grazier KL. An examination of costs, charges, and payments for inpatient psychiatric treatment in community hospitals. Psychiatr Serv. 2012;63(7):666–671. doi:10.1176/appi.ps.201100402
   PubMed Web of Science ®Google Scholar
• Lindamer LA, Liu L, Sommerfeld DH, et al. Predisposing, enabling, and need factors associated with high service use in a public mental health system. Adm Policy Ment Health. 2012;39(3):200–209. doi:10.1007/s10488-011-0350-3
   PubMed Web of Science ®Google Scholar
• Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 2008;59(10):1175–1183. doi:10.1176/ps.2008.59.10.1175
   PubMed Web of Science ®Google Scholar
• Busch AB, Yoon F, Barry CL, et al. The effects of mental health parity on spending and utilization for bipolar, major depression, and adjustment disorders. Am J Psychiatry. 2013;170(2):180–187. doi:10.1176/appi.ajp.2012.12030392
   Web of Science ®Google Scholar
• Gianfrancesco FD, Sajatovic M, Rajagopalan K, Wang RH. Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. Clin Ther. 2008;30(7):1358–1374. doi:10.1016/S0149-2918(08)80062-8
   PubMed Web of Science ®Google Scholar
• Guo JJ, Keck PE Jr, Li H, Jang R, Kelton CM. Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population. Value Health. 2008;11(3):416–423. doi:10.1111/j.1524-4733.2007.00287.x
   PubMed Web of Science ®Google Scholar
• Kim E, You M, Pikalov A, Van-Tran Q, Jing Y. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis. BMC Psychiatry. 2011;11(1):6. doi:10.1186/1471-244X-11-6
   Web of Science ®Google Scholar
• Stensland MD, Schultz JF, Frytak JR. Depression diagnoses following the identification of bipolar disorder: costly incongruent diagnoses. BMC Psychiatry. 2010;10(1):39. doi:10.1186/1471-244X-10-39
   Web of Science ®Google Scholar
• Stensland MD, Schultz JF, Frytak JR. Diagnosis of unipolar depression following initial identification of bipolar disorder: a common and costly misdiagnosis. J Clin Psychiatry. 2008;69(5):749–758. doi:10.4088/JCP.v69n0508
   Web of Science ®Google Scholar
• Correll CU, Ng-Mak DS, Stafkey-Mailey D, Farrelly E, Rajagopalan K, Loebel A. Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. Ann Gen Psychiatry. 2017;16(1):9. doi:10.1186/s12991-017-0133-7
   PubMed Web of Science ®Google Scholar
• Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm. 2009;66(4):358–365. doi:10.2146/ajhp080374
   Web of Science ®Google Scholar
• Lage MJ, Hassan MK. The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Ann Gen Psychiatry. 2009;8(1):7. doi:10.1186/1744-859X-8-7
   PubMedGoogle Scholar
• Bagalman E, Yu-Isenberg KS, Durden E, Crivera C, Dirani R, Bunn WB 3rd. Indirect costs associated with nonadherence to treatment for bipolar disorder. J Occup Environ Med. 2010;52(5):478–485. doi:10.1097/JOM.0b013e3181db811d
   PubMed Web of Science ®Google Scholar
• Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry. 2010;71(3):296–303. doi:10.4088/JCP.09m05514yel
   PubMed Web of Science ®Google Scholar
• Brooks JO, Goldberg JF, Ketter TA, et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the systematic treatment enhancement program for bipolar disorder. J Clin Psychiatry. 2011;72(2):240–247. doi:10.4088/JCP.09m05214yel
   Web of Science ®Google Scholar
• Pelletier E, Hassan M, Alemayehu B, Smith D, Kim J. Bipolar disorder healthcare costs for quetiapine extended-release versus aripiprazole. Am J Pharm Benefits. 2013;5(3):e73–e79.
   Google Scholar
• Rascati KL, Richards KM, Ott CA, et al. Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. Psychiatr Serv. 2011;62(9):1032–1040. doi:10.1176/ps.62.9.pss6209_1032
   PubMed Web of Science ®Google Scholar
• Qiu Y, Christensen DB, Fu AZ, Liu GG. Cost analysis in a medicaid program for patients with bipolar disorder who initiated atypical antipsychotic monotherapy. Curr Med Res Opin. 2009;25(2):351–361. doi:10.1185/03007990802634077
   PubMed Web of Science ®Google Scholar
• Qiu Y, Fu AZ, Liu GG, Christensen DB. Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a medicaid programme. Appl Health Econ Health Policy. 2010;8(3):167–177. doi:10.2165/11318830-000000000-00000
   PubMedGoogle Scholar
• McMorris BJ, Downs KE, Panish JM, Dirani R. Workplace productivity, employment issues, and resource utilization in patients with bipolar I disorder. J Med Econ. 2010;13(1):23–32. doi:10.3111/13696990903475833
   PubMedGoogle Scholar
• Petrila J, Andel R, Constantine R, Robst J. Public expenditures related to the criminal justice system and to services for arrestees with a serious mental illness. Psychiatr Serv. 2010;61(5):516–519. doi:10.1176/ps.2010.61.5.516
   Web of Science ®Google Scholar
• Shippee ND, Shah ND, Williams MD, Moriarty JP, Frye MA, Ziegenfuss JY. Differences in demographic composition and in work, social, and functional limitations among the populations with unipolar depression and bipolar disorder: results from a nationally representative sample. Health Qual Life Outcomes. 2011;9(1):90. doi:10.1186/1477-7525-9-90
   Web of Science ®Google Scholar
• O’Donnell LA, Deldin PJ, Grogan-Kaylor A, et al. Depression and executive functioning deficits predict poor occupational functioning in a large longitudinal sample with bipolar disorder. J Affect Disord. 2017;215:135–142. doi:10.1016/j.jad.2017.03.015
   PubMed Web of Science ®Google Scholar
• Peters AT, West AE, Eisner L, Baek J, Deckersbach T. The burden of repeated mood episodes in bipolar i disorder: results from the national epidemiological survey on alcohol and related conditions. J Nerv Ment Dis. 2016;204(2):87–94. doi:10.1097/NMD.0000000000000425
   Web of Science ®Google Scholar
• Simon GE, Ludman EJ, Unutzer J, Operskalski BH, Bauer MS. Severity of mood symptoms and work productivity in people treated for bipolar disorder. Bipolar Disord. 2008;10(6):718–725. doi:10.1111/j.1399-5618.2008.00581.x
   PubMed Web of Science ®Google Scholar
• Chatterton ML, Ke X, Lewis BE, Rajagopalan K, Lazarus A. Impact of bipolar disorder on the family: utilization and cost of health care resources. P T. 2008;33(1):15–34.
   Google Scholar
• American Diabetes A. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–928. doi:10.2337/dci18-0007
   PubMed Web of Science ®Google Scholar
• Chessick CA, Perlick DA, Miklowitz DJ, et al. Suicidal ideation and depressive symptoms among bipolar patients as predictors of the health and well-being of caregivers. Bipolar Disord. 2009;11(8):876–884. doi:10.1111/j.1399-5618.2009.00765.x
   Web of Science ®Google Scholar
• Bobo WV. The diagnosis and management of bipolar I and II disorders: clinical practice update. Mayo Clin Proc. 2017;92(10):1532–1551. doi:10.1016/j.mayocp.2017.06.022
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008;23(2):95–105. doi:10.1002/hup.908
   PubMed Web of Science ®Google Scholar
• Mago R, Borra D, Mahajan R. Role of adverse effects in medication nonadherence in bipolar disorder. Harv Rev Psychiatry. 2014;22(6):363–366. doi:10.1097/HRP.0000000000000017
   PubMed Web of Science ®Google Scholar
• Kern JS, Cerimele JM. Collaborative care for patients with a bipolar disorder: a primary care FQHC-CMHC partnership. Psychiatr Serv. 2019;70(4):353. doi:10.1176/appi.ps.201900019
   Web of Science ®Google Scholar
• Kilbourne AM, Barbaresso MM, Lai Z, et al. Improving physical health in patients with chronic mental disorders: twelve-month results from a randomized controlled collaborative care trial. J Clin Psychiatry. 2017;78(1):129–137. doi:10.4088/JCP.15m10301
   PubMed Web of Science ®Google Scholar
• Kilbourne AM, Goodrich DE, O’Donnell AN, Miller CJ. Integrating bipolar disorder management in primary care. Curr Psychiatry Rep. 2012;14(6):687–695. doi:10.1007/s11920-012-0325-4
   PubMed Web of Science ®Google Scholar
• Wright WA, Gorman JM, Odorzynski M, Peterson MJ, Clayton C. Integrated pharmacies at community mental health centers: medication adherence and outcomes. J Manag Care Spec Pharm. 2016;22(11):1330–1336.
   Web of Science ®Google Scholar
• Angst J. Bipolar disorders in DSM-5: strengths, problems and perspectives. Int J Bipolar Disord. 2013;1(1):12. doi:10.1186/2194-7511-1-12
   Google Scholar
• Stensland MD, Zhu B, Ascher-Svanum H, Ball DE. Costs associated with attempted suicide among individuals with bipolar disorder. J Ment Health Policy Econ. 2010;13(2):87–92.
   Web of Science ®Google Scholar
• Seabury SA, Goldman DP, Kalsekar I, Sheehan JJ, Laubmeier K, Lakdawalla DN. Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid. Am J Manag Care. 2014;20(2):e52–60.
   Web of Science ®Google Scholar
• Robertson AG, Swanson JW, Lin H, Easter MM, Frisman LK, Swartz MS. Influence of criminal justice involvement and psychiatric diagnoses on treatment costs among adults with serious mental illness. Psychiatr Serv. 2015;66(9):907–909. doi:10.1176/appi.ps.201500134
   PubMed Web of Science ®Google Scholar